Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Companies

Set Alert for Companies

Takeda’s Andy Plump Tells The Japanese Pharma’s New Story

As Takeda pays down debt associated with the acquisition of Shire and advances R&D programs toward global filings, the company is selling its growth plan to investors – but are they buying?

Business Strategies Research and Development Strategies

Real-World Data Confirm Pfizer and AZ COVID-19 Vaccine Efficacy – And Bolster UK Dosing Policy

Observational studies from the National Health Service show encouraging signs for the UK’s vaccination program.

Commercial Companies

Pfizer Embraces Biotech-Like Speed To Advance BCMA Bispecific

Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.

Research and Development Strategies Business Strategies

Stockwatch: The Pandemic’s Effects On Big Pharma – A Year In

Depending on the therapeutic area, a fall in pharmaceutical sales was an obvious effect of the pandemic, although lower selling and marketing expenses and fewer non-COVID-19 infections were minor positives.

Stockwatch Companies

Coronavirus Update: Pfizer Pledges To Double US Vaccine Output

A round-up of the latest developments, including Celltrion’s new antibody cocktail and SK Biosience and Novavax expanding their collaboration.

Coronavirus COVID-19 Companies

Early-Stage R&D In The Spotlight As BMS Patent Expirations Approach

With the first Revlimid generics launching in 2022, Bristol Myers Squibb’s late-stage assets are key, but earlier programs will help fill the void as Opdivo and Eliquis lose exclusivity later in the decade.

Research and Development Strategies Deals

Pfizer And Moderna Reap Rewards Of Expanded US And EU Deals

The two rival mRNA vaccines are proving attractive in the face of new variants, and could dominate once SARS-CoV2 enters the ‘endemic’ stage.

Commercial Companies

4D Pharma Joins The SPAC Trend To Fund Its Keytruda-Boosting Biotherapeutic

The Leeds, UK-based company is looking to the alternative route to the US stock market to fund its live biotherapeutics platform.

Europe United Kingdom

One To Watch: Ruling On AZ’s First-In-Class Anemia Drug Roxadustat Expected Shortly

AstraZeneca is in pole position to open up the HIF-PH inhibitor market – but GSK has a rival in the wings.

Commercial Companies
See All
UsernamePublicRestriction

Register